This paper uses MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and then uses these preferences to assess the value of obinutuzumab for rituximab-refractory iNHL.
OHE has just published two new briefings entitled ‘New Age Decision Making in HTA’ and ‘How Can HTA in Asia-Pacific Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?’. Both publications are reports of panel sessions held at the HTAi 2016 meeting in Tokyo.
The biannual EuHEA Conference was held at the Hamburg Center for Health Economics (HCHE), 13-16th July 2016. The topic of the meeting was “Know the Ropes - Balancing Costs and Quality in Health Care”. Members of the OHE team attended and contributed to the conference; this post summarises their activity.
“Complementary diagnostics” are defined as tests using biomarkers for risk assessment, diagnosis, prognosis, monitoring, and guiding therapeutic decisions. This White Paper presents a more comprehensive framework for considering their value contribution.